natgillin/translations-raw huggingface dataset:
Fortæl det til din læge, hvis du er afhængig af alkohol, epilepsi eller lider af leversvækkelse. 
Discuss with your doctor if you suffer from alcohol dependency, epilepsy, or liver impairment.
Median TTP var 37,3 uger (95 % CI: 33,4 - 42,1) i AT-armen og 31,9 uger (95 % CI: 27,436,0) i AC-armen. 
The median TTP was 37.3 weeks (95% CI: 33.4 - 42.1) in AT arm and 31.9 weeks (95% CI:
• træthed eller influenza-lignende symptomer 
• tiredness or flu-like symptoms
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af CYP3A, f.eks. ciclosporin, ketoconazol og erythromycin. 
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin.
Tidligere behandling skal have omfattet et anthracyklin. 
Previous therapy should have included an anthracycline.
Efter stratificering i henhold til antallet af positive lymfeknuder (1-3, 4+), blev 1.491 patienter randomiseret til enten at få enten docetaxel 75 mg/m2 administreret en time efter doxorubicin 50 
After stratification according to the number of positive lymph nodes (1-3, 4+), 1,491 patients were randomized to receive either docetaxel 75 mg/m2 administered 1-hour after doxorubicin
Hos patienter, som får kompliceret neutropeni (forlænget neutropeni, febril neutropeni eller infektion), bør G-CSF og dosisreduktion overvejes (se pkt.4.2). 
For patients who experience complicated neutropenia (prolonged neutropenia, febrile neutropenia or infection), G-CSF and dose reduction should be considered (see section 4.2).
Docetaxels kinetiske profil er dosisuafhængig og svarer til en trekamret farmakokinetisk model med halveringstider for α-, β- og γ-faserne på henholdsvis 4 min., 36 min. og 11,1 timer. 
The kinetic profile of docetaxel is dose independent and consistent with a three-compartment pharmacokinetic model with half lives for the α, β and γ phases of 4 min, 36 min and 11.1 h, respectively.
Efter kemoterapi bør patienterne have strålebehandling. 
Following chemotherapy, patients should receive radiotherapy.
Det primære endepunkt i dette studie, progressionsfri overlevelse (PFS), var signifikant længere i TPF-armen end i PF-armen, p = 0,0042 (median PFS: henholdsvis 11,4 og 8,3 måneder) med en overordnet median opfølgningstid på 33,7 måneder. 
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs. 8.3 months respectively) with an overall median follow up time of 33.7 months.
Ældre 
Elderly people
Hvis koncentratet eller infusionsopløsningen med Taxespira kommer i kontakt med huden, afvaskes området straks grundigt med sæbe og vand. 
If Taxespira concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Tre patienter (2 %), der fik docetaxel, ophørte med behandlingen grundet væskeretention, hvorimod 15 patienter (9 %), der fik doxorubicin, stoppede behandlingen grundet hjertetoksicitet (3 tilfælde af fatalt, kongestivt hjertesvigt). 
Three docetaxel patients (2%) discontinued the treatment due to fluid retention, whereas 15 doxorubicin patients (9%) discontinued due to cardiac toxicity (three cases of fatal congestive heart failure).
Hyppigheden af relateret feber, diarré, anoreksi og perifere ødemer var ≥ 10 % højere hos patienter som var 75 år eller ældre end hos patienter under 65 år. 
The incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred at rates ≥ 10 % higher in patients who were 75 years of age or greater versus less than 65 years.
Derimod kræver svære overfølsomhedsreaktioner såsom svær hypotension, bronkospasme eller generaliseret udslæt/erythem, øjeblikkelig afbrydelse af docetaxel-infusion og passende terapi. 
However, severe reactions, such as severe hypotension, bronchospasm or generalised rash/erythema require immediate discontinuation of docetaxel and appropriate therapy.
Median antal af cyklusser administreret pr. patient var 6 (med et interval på 1-16) for TCF-armen sammenlignet med 4 (med et interval på 1-12) for CF-armen. 
The median number of cycles administered per patient was 6 (with a range of 1-16) for the TCF arm compared to 4 (with a range of 1-12) for the CF arm. Time to progression (TTP) was the primary endpoint.
- Øvrige indholdsstoffer: polysorbat 80, vandfri ethanol (se punkt 2) og citronsyremonohydrat. 
- The other ingredients are polysorbate 80, ethanol anhydrous (see section 2) and citric acid monohydrate.
Sygdomsfri overlevelse 
Disease free survival
Da fordelene hos patienter med 4+ lymfeknuder ikke var statistisk signifikant for DFS og OS, blev den positive benefit/risk-fordeling for TAC hos patienter med 4+ lymfeknuder ikke helt demonstreret ved den endelige analyse. 
As the benefit observed in patients with 4 + nodes was not statistically significant on DFS and OS, the positive benefit/risk ratio for TAC in patients with 4 + nodes was not fully demonstrated at the final analysis.
I dette studie blev 501 patienter med lokalt fremskreden SCCHN og WHO performance status 0 eller 1 randomiseret til en af to behandlingsarme. 
In this study, 501 patients, with locally advanced SCCHN, and a WHO performance status of 0 or 1, were randomized to one of two arms.
Er du i tvivl om anvendelsen af dette lægemiddel, så spørg lægen eller apotekspersonalet på hospitalet. 
If you have any further questions on the use of this medicine, ask your doctor, or hospital pharmacist.
Overfølsomhedsreaktioner opstod generelt inden for få minutter efter starten af docetaxel-infusionen, og reaktionerne var ofte milde til moderate. 
Hypersensitivity reactions have generally occurred within a few minutes following the start of the infusion of docetaxel and were usually mild to moderate.
In vitro-studier har vist, at docetaxel ødelægger det mikrotubulære netværk i celler, som er essentielle for mitosen og cellulære funktioner i interfasen. 
Docetaxel has been shown in vitro to disrupt the microtubular network in cells which is essential for vital mitotic and interphase cellular functions.
Mediantiden indtil progression var 186 dage (docetaxel+ capecitabin) vs. 128 dage (docetaxel alene). 
The median time to progression was 186 days (docetaxel + capecitabine) vs. 128 days (docetaxel alone).
Lokoregional behandling med stråling blev givet enten med en konventionel fraktion (1,8 Gy-2,0 Gy én gang dagligt 5 dage om ugen til en total dosis på 66 til 70 Gy) eller accelererede/hyperfraktionerede regimener af strålebehandling (to gange dagligt med et minimumsinterfraktionsinterval på 6 timer, 5 dage pr. uge). 
Locoregional therapy with radiation was delivered either with a conventional fraction (1.8 Gy - 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week).
Bland opløsningen i infusionsposen eller -flasken manuelt med vippende bevægelser. 
Mix the infusion bag or bottle manually using a rocking motion.
Forekomsten af febril neutropeni/neutropenisk sepsis var også forhøjet hos de patienter, der fik behandling med Herceptin plus docetaxel (23 % vs. 17 % for de patienter, der fik behandling med docetaxel alene). 
The incidence of febrile neutropenia/neutropenic sepsis was also increased in patients treated with Herceptin plus docetaxel (23% versus 17% for patients treated with docetaxel alone).
• sløret syn på grund af hævelse på øjets nethinde (cystoidt makulaødem) 
• blurred vision due to swelling of the retina within the eye (cystoid macular oedema)
Meget almindelig: Hæmatologisk toksicitet var forhøjet hos de patienter, som fik trastuzumab og docetaxel, sammenlignet med de patienter, som fik behandling med docetaxel alene (32 % grad 3/4 neutropeni vs. 22 % med anvendelse af NCI-CTC-kriterierne). 
Very common: Haematological toxicity was increased in patients receiving trastuzumab and docetaxel, compared with docetaxel alone (32% grade 3/4 neutropenia versus 22%, using NCI-CTC criteria).
Den opdaterede analyse blev udført, da alle patienter havde nået deres 10-års (median opfølgningstid var 10 år og 5 måneder) opfølgningsbesøg (medmindre de havde DFS eller tidligere var udgået fra opfølgning). 
The updated analysis was performed when all patients had reached their 10-year (median follow up time of 10 years and 5 months) follow-up visit (unless they had a DFS event or were lost to follow-up previously).
• ventrikulær arytmi eller ventrikulær takykardi (manifesteret som uregelmæssig og/eller hurtig hjerterytme, alvorlig åndenød, svimmelhed og/eller besvimelse). 
• ventricular arrhythmia or ventricular tachycardia (manifested as irregular and/or rapid heartbeat,
Flere grad 3/4 bivirkninger blev observeret for monoterapi med docetaxel (55,4 %) sammenlignet med paclitaxel (23,0 %). 
More grade 3/4 adverse events were observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).
• 332 patienter, som fik docetaxel i kombination med prednison eller prednisolon (klinisk relevante behandlingsrelaterede bivirkninger er medtaget). 
• 332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).
Fra et mikrobiologisk synspunkt skal rekonstitution/fortynding foretages under kontrollerede og aseptiske forhold. 
From a microbiological point of view, reconstitution/dilution must take place in controlled and aseptic conditions.
Nervesystemet Udvikling af alvorlig perifer neurotoksicitet kræver en dosisreduktion (se pkt. 
Nervous system The development of severe peripheral neurotoxicity requires a reduction of dose (see section 4.2).
Ved den mediane opfølgningsperiode på 77 måneder blev der vist signifikant længere sygdomsfri overlevelse (DFS) i TAC-armen sammenlignet med FAC-armen. 
At the median follow-up time of 77 months, significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
For opbevaringsforhold for det fortyndede lægemiddel, se pkt. 
For storage conditions of the diluted medicinal product, see section 6.3.
Koncentratet er en svagt gul til brun-gul opløsning. 
The concentrate is a pale yellow to brownish-yellow solution.
Patienter uden progressiv sygdom skulle have (CRT) ifølge protokollen (PF/CRT). 
All patients who did not have progressive disease were to receive CRT as per protocol (PF/CRT).
Medianoverlevelsen var 442 dage (docetaxel + capecitabin) vs. 352 dage (docetaxel alene). 
Median survival was 442 days (docetaxel + capecitabine) vs. 352 days (docetaxel alone).
Adjuverende stråleterapi blev givet i henhold til eksisterende vejledninger i de deltagende centre og blev givet til 69 % af patienterne, som fik TAC, og 72 % af patienterne, som fik FAC. 
Adjuvant radiation therapy was prescribed according to guidelines in place at participating institutions and was given to 69 % of patients who received TAC and 72% of patients who received FAC.
Hos patienter i behandling med TAC-regimenet for lymfeknude-positiv brystkræft har risikoen for CHF vist sig at være højere i det første år efter behandling (se pkt. 
In patients treated with the TAC regimen for node positive breast cancer, the risk of CHF has been shown to be higher during the first year after treatment (see sections 4.8 and 5.1).
Der er rapporter om anafylaktisk shock, i nogle tilfælde fatale. 
Some cases of anaphylactic shock, sometimes fatal, have been reported.
Blandt 300 patienter (221 patienter i fase III-delen af studiet og 79 patienter i fase II-delen af studiet), som fik behandling med docetaxel i kombination med cisplatin og 5-fluoruracil i studiet af gastrisk kræft, var 74 patienter 65 år eller ældre, og 4 patienter var 75 år eller ældre. 
Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
I tilfælde af efterfølgende episoder med kompliceret neutropeni bør dosis af docetaxel reduceres fra 60 mg/m til 45 mg/m 2. 
If subsequent episodes of complicated neutropenia occur the docetaxel dose should be reduced from 60 to 45 mg/m2.
Stomatitis/mucositis grad 3 Første episode: Reducer 5-FU-dosis med 20 %. 
Stomatitis/mucositis grade 3 First episode: reduce 5-FU dose by 20%.
Der blev påvist signifikant længere sygdomsfri overlevelse i TAC-armen end i FAC-armen. 
Significantly longer disease-free survival for the TAC arm compared to the FAC arm was demonstrated.
• betændelse i øjet eller øget tåreflåd 
• inflammation of the eye or increased tearing of the eyes
Docetaxel øgede responsraten (33 % vs. 12 %, p < 0,0001), forlængede tiden til progression (19 uger vs. 11 uger, p = 0,0004) og forlængede overlevelsen (11 måneder vs. 9 måneder, p = 0,01). 
Docetaxel increased response rate (33% vs. 12%, p <0.0001), prolonged time to progression (19 weeks vs. 11 weeks, p = 0.0004) and prolonged OS (11 months vs. 9 months, p = 0.01).
De mest almindeligt indberettede bivirkninger af Taxespira alene er: fald i antallet af røde og hvide blodlegemer, hårtab (alopeci), kvalme, opkastning, sår i munden, diarré og træthed. 
The most commonly reported adverse reactions of Taxespira alone are: decrease in the number of red blood cells or white blood cells, alopecia (hair loss), nausea, vomiting, sores in the mouth, diarrhoea and tiredness.
Taxespira i kombination med doxorubicin og cyclophosphamid er indiceret til adjuverende behandling af patienter med: 
Taxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:
Akut respiratorisk distress syndrom og tilfælde af interstitiel pneumoni/pneumonitis, interstitiel lungesygdom, lungefibrose og respirationssvigt, sommetider fatale, er rapporteret sjældent. 
Acute respiratory distress syndrome and cases of interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported.
I dette studie blev 358 patienter med inoperabel, lokalt fremskreden SCCHN og WHO performance status 0 eller 1 randomiseret til en af to behandlingsarme. 
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomized to one of two treatment arms.
Alvorlige reaktioner var kendetegnet ved hypotension og/eller bronkospasmer eller generaliseret udslæt/erytem (se pkt. 
Severe reactions were characterised by hypotension and/or bronchospasm or generalized rash/erythema (see section 4.4).
Dehydrering og lungeødem er sjældent rapporteret. 
Dehydration and pulmonary oedema have rarely been reported.
Til behandling af patienter med lokalt fremskreden eller metastatisk brystkræft er den anbefalede dosis docetaxel i monoterapi 100 mg/m 2. 
For the treatment of patients with locally advanced or metastatic breast cancer, the recommended dose of docetaxel is 100 mg/m2 in monotherapy.
• Hos patienter, der første gang udvikler grad 2-toksicitet, der vedvarer til tidspunktet for den næste behandling med docetaxel/capecitabin, skal behandlingen udsættes, indtil toksiciteten er grad 0-1, og derefter genoptages som 100 % af den oprindelige dosis. 
• For patients developing the first appearance of Grade 2 toxicity, which persists at the time of the next docetaxel/capecitabine treatment, delay treatment until resolved to Grade 0-1, and resume at 100% of the original dose.
Fordeling Efter administration af docetaxel 100 mg/m2 givet som infusion over 1 time blev en gennemsnitlig, maksimal plasmakoncentration på 3,7 µg/ml opnået med et tilsvarende AUC på 4,6 t.µg/ml. 
Distribution Following the administration of a 100 mg/m2 dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Median OS var også signifikant længere til fordel for TPF-armen sammenlignet med PF-armen (median OS: henholdsvis 18,6 og 14,5 måneder) med en reduktion af risikoen for mortalitet på 28 %, p = 0,0128. 
Median OS was also significantly longer in favour of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5 months respectively) with a 28% risk reduction of mortality, p = 0.0128.
Taxespira som enkeltstof 
Taxespira as single agent
Hvert hætteglas er til engangsbrug og bør anvendes umiddelbart efter anbrud. 
Each vial is for single use and should be used immediately after opening.
Der er rapporteret meget sjældne tilfælde af forbigående synsforstyrrelser (glimt, lysglimt, pletter i synsfeltet), typisk forekommende under infusion af lægemidlet og i forbindelse med overfølsomhedsreaktioner. 
Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported.
Docetaxels plasmaproteinbinding er over 95 %. 
Docetaxel is more than 95% bound to plasma proteins.
For eksempel vil en dosis på 140 mg docetaxel kræve 7 ml Taxespira 20 mg/1 ml koncentrat til infusionsvæske, opløsning. 
For example, a dose of 140 mg docetaxel would require 7 ml Taxespira 20 mg/1 ml concentrate for solution for infusion.
Docetaxel har vist sig at være mutagent in vitro i mikronukleus- og kromosom-aberrationstesten i CHO-K1 celler samt in vivo i mikronukleustesten i mus. 
Docetaxel has been shown to be mutagenic in the in vitro micronucleus and chromosome aberration test in CHO-K1 cells and in the in vivo micronucleus test in the mouse.
Patienter med et neutrofiltal ved baseline på < 1.500 celler/mm 
Patients with baseline neutrophil count of <1,500 cells/mm
Øsofagitis (alvorlig: 
Oesophagitis (severe:
Docetaxel + trastuzumab var effektivt til patienterne, uanset om de havde fået adjuverende anthracyclin eller ikke. 
Docetaxel plus trastuzumab was efficacious in patients whether or not they had received prior adjuvant anthracyclines.
• maveproblemer, herunder kvalme, opkastning og diarré, forstoppelse 
• stomach upsets including nausea, vomiting and diarrhoea, constipation
Adjuverende strålebehandling blev administreret i henhold til retningslinjerne for de deltagende behandlingssteder og blev givet til 57,3 % af de patienter, der fik TAC, og til 51,2 % af de patienter, der fik FAC. 
Adjuvant radiation therapy was administered according to guidelines in place at participating institutions and was given to 57.3 % of patients who received TAC and 51.2 % of patients who received FAC.
Der er ingen relevant anvendelse af Taxespira i den pædiatriske population til indikationerne brystkræft, ikke-småcellet lungekræft, prostatakræft, gastrisk karcinom samt hoved- og halskræft med undtagelse af type II og III lavt differentieret nasofaryngealt karcinom. 
There is no relevant use of Taxespira in the paediatric population for the indication of breast cancer, non-small cell lung cancer, prostate cancer, gastric carcinoma and head and neck cancer, not including type II and III less differentiated nasopharyngeal carcinoma.
ORR var 59,3 % (95 % CI: 52,8 - 65,9) i AT-armen vs. 46,5 % (95 % CI: 39,8 - 53,2) i AC-armen. 
The ORR was 59.3% (95% CI: 52.8 - 65.9) in AT arm versus 46.5% (95% CI: 39.8 - 53.2) in
• blodpropper. 
• blood clots.
mg/m2 (TAC-arm) eller doxorubicin 50 mg/m 2, efterfulgt af fluoruracil 500 mg/m2 (FAC-arm). 
50 mg/m2 (TAC arm), or doxorubicin 50 mg/m 2 followed by fluorouracil 500 mg/m2 (FAC arm).
I behandlingsarmen på docetaxel plus trastuzumab havde 64 % fået tidligere behandling med antracyclin som adjuverende behandling sammenlignet med 55 % i behandlingsarmen på docetaxel alene. 
In the docetaxel plus trastuzumab arm, 64% had received a prior anthracycline as adjuvant therapy compared with 55% in the docetaxel arm alone.
Med en hazard ratio på under 1 kan docetaxel + cisplatin + 5-FU anvendes med fordel *Cox-model (justering for primært tumorsted, kliniske T- og N-stadier og PSWHO) **Log-rank-test *** Chi-kvadrat-test 
A hazard ratio of less than 1 favours docetaxel + cisplatin + 5-FU *Cox model (adjustment for Primary tumour site, T and N clinical stages and PSWHO) **Logrank test *** Chi-square test
• lungebetændelse (pneumoni) 
• pneumonia (infection of the lungs)
Sikkerheden og effekten af docetaxel i kombination med prednison eller prednisolon hos patienter med hormonrefraktær prostatakræft blev undersøgt i et randomiseret fase III-multicenterstudie. 
The safety and efficacy of docetaxel in combination with prednisone or prednisolone in patients with hormone refractory metastatic prostate cancer were evaluated in a randomized multicenter phase III study.
Docetaxel er et antineoplastisk stof, og ligesom andre potentielt toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af opløsningerne. 
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions.
Ydre karton 
Outer Carton
Patienter, der tidligere har fået behandling med kemoterapi med eller uden strålebehandling I et fase III-studie med tidligere behandlede patienter var tiden indtil progression (12,3 uger vs. 7 uger) og den overordnede overlevelse signifikant længere for docetaxel ved doseringen 75 mg/m² end for bedste palliative behandling. 
Patients previously treated with chemotherapy with or without radiotherapy In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and OS were significantly longer for docetaxel at 75 mg/m² compared to Best Supportive Care.
Patienter med 4+ lymfeknuder 
Patients with 4+ nodes
Hjælpestoffer: polysorbat 80, vandfri ethanol (læs indlægssedlen for yderligere information), citronsyremonohydrat. 
Excipients: polysorbate 80, ethanol anhydrous (see leaflet for further information), citric acid monohydrate.
Der blev udført eksplorative undergruppeanalyser af sygdomsfri overlevelse for patienter, der opfylder kriterierne for kemoterapi ifølge 2009 St. Gallen-kriterierne - (ITT-population). 
Exploratory subgroup analyses for disease-free survival for patients who meet the 2009 St. Gallen chemotherapy criteria - (ITT population) were performed and presented here below:
Taxespira er et antineoplastisk stof, og ligesom andre potentielt toksiske stoffer skal det behandles med forsigtighed ved håndtering og tilberedning af opløsningerne med Taxespira. 
Taxespira is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing Taxespira solutions.
Hvis samtidige anvendelse af en potent CYP3A4-hæmmer (f.eks. ketoconazol, itraconazol, clarithromycin, indinavir, nefazodon, nelfinavir, ritonavir, saquinavir, telithromycin og voriconazol) ikke kan undgås, er tæt klinisk overvågning nødvendig, og dosisjustering af docetaxel kan være hensigtsmæssig under behandling med potente CYP3A4-hæmmere (se pkt. 
If the concomitant use of a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole) cannot be avoided, a close clinical surveillance is warranted and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor (see section 4.4).
256 patienter blev randomiseret til behandling med docetaxel alene (100 mg/ m som 1 times intravenøs infusion hver 3. uge). 
256 patients were randomised to treatment with docetaxel alone (100 mg/m2 as a 1 hour intravenous infusion every 3 weeks).
Vær særlig opmærksom på at informere din læge, hvis du får diarré, sår i munden, følelsesløshed, stikkende og prikkende fornemmelser eller feber, og giv lægen resultatet af dine blodprøver. 
In particular, please inform your doctor in case of diarrhoea, sores in the mouth, feeling of numbness or pins and needles, fever and give her/him the results of your blood tests.